跳至主要内容
临床试验/EUCTR2011-001935-21-IT
EUCTR2011-001935-21-IT进行中(未招募)不适用

An interventional non-therapeutic study to assess ex vivo basophil activation in response to various preparations of taspoglutide and related items in blood samples from subjects who previously received taspoglutide and experienced a systemic allergic reactuin

IPSEN PHARMA SAS0 个研究点目标入组 29 人开始时间: 2011年12月29日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
29

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • •- Subjects who, during one of the Roche T-Emerge Programme studies,
  • •experienced a serious or non-serious adverse event (AE) that is
  • •suggestive of a possible systemic allergic reaction to the study drug (per
  • •the Investigator's assessment).
  • •- Ability and willingness to give written informed consent and to provide
  • •a blood sample for the BAT.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 13
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 7

排除标准

  • •Subjects who participated in any other clinical study within 30 days
  • •prior to screening or who may enter another clinical study during the
  • •course of this study.
  • •Subjects who experienced a systemic allergic reaction, during one of
  • •the Roche T-Emerge Programme Studies, more than 24 months prior to
  • •Subjects who received immunosuppressants within 1 week prior to
  • •Subjects who received any GLP-1 mimetic/analogue other than
  • •taspoglutide at any time.
  • •Subjects who received taspoglutide since the last administration in
  • •the T-Emerge Programme.

研究者

相似试验